



SelectImmune Pharma reports significant patent progress across the project portfolio

SelectImmune Pharma is pleased to announce a continued strengthening of its intellectual property portfolio through a number of recent patent grants.

Following extensive research into the treatment of cystitis using interleukin-1 receptor antagonists (IL1-RA), patent protection was sought in Europe, the US and Australia. The US and Australian patent offices granted protection in May of this year and the European Patent Office recently announced acceptance of the patent claims. Grant of the European patent is therefore expected to follow soon.

SelectImmune Pharma continues to seek protection over further cystitis therapeutics. In particular, protection over MMP7 inhibitors for the treatment of cystitis will be granted to SelectImmune Pharma in Europe in mid-August and based on the strength of this success protection will soon be sought elsewhere.

In a further success, the European Patent Office will soon grant to SelectImmune Pharma protection over therapeutic uses of *E. coli* NlpD or Sigma S proteins. The protection broadly covers any therapy where these proteins may be useful, and it is noted that these proteins appear particularly promising in immunosuppression, anti-inflammation and anti-infection roles.

"We are delighted to see our discovery efforts are being rewarded and are grateful for the excellent support from our Intellectual property partner," says Catharina Svanborg, Chairman of the board, SelectImmune Pharma.

For more information, please contact:

Catharina Svanborg

Chairman of the board SelectImmune Pharma AB

Phone: +46 709 42 65 49

E-mail: catharina.svanborg@med.lu.se

Ann Gidner

CEO SelectImmune Pharma AB

Phone: +46 768 17 14 14

E-mail: ann.gidner@selectimmune.com

This disclosure contains information that SelectImmune is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 13-08-2021 11:50 CET.

SelectImmune Pharma is a pharmaceutical company whose shares are traded on the Spotlight Stock Market. The company goal is to develop new immunotherapies, which act as immune enhancers and offer alternatives to antibiotics.

Bacterial infections affect large parts of the population and are becoming increasingly difficult to treat due to increasing antibiotic resistance. SelectImmune Pharma develops immunotherapies that can supplement or replace antibiotics. Urinary tract infections (UTI) are one of the world's most common infectious diseases, affecting about 150 million people each year. The need for alternative treatments for bacterial infections is currently very large as are potential markets.